Efficacy and safety of different ticagrelor regimens versus clopidogrel in patients with coronary artery disease: a retrospective multicenter study (SUPERIOR)

Autor:	Jing Shi, Meijiao He, Wennan Wang, Guangzhong Liu, Haiyu Zhang, Danghui Sun, Jianqiang Li, Hongyuan Mu, Minglu Xu, Chenyang Zhao, Jiayu Wang, Chongyang Zhang, Hai Cang, Shiqi Zhao, Zhiren Zhang, Yue Li
Jazyk:	angličtina
Rok vydání:	2021
Předmět:	bleeding clopidogrel inhibition of platelet aggregation low-dose ticagrelor Diseases of the blood and blood-forming organs RC633-647.5
Zdroj:	Platelets, Vol 32, Iss 1, Pp 120-129 (2021)
Druh dokumentu:	article
ISSN:	0953-7104 1369-1635 09537104
DOI:	10.1080/09537104.2020.1732328
Popis:	Current guidelines favor dual anti-platelet therapy with ticagrelor 90 mg BID (T90BID) over clopidogrel 75 mg QD (C75QD) in addition to aspirin for acute coronary syndrome. However, an increased risk of ticagrelor-related adverse events prompted the evaluation of low-dose regimens. This study (NCT03381742) retrospectively analyzed the data from 11 hospitals on 3,043 patients with coronary artery disease, who received C75QD, T90BID, ticagrelor 45 mg BID (T45BID), or ticagrelor 90 mg QD (T90QD). Compared with C75QD, both T45BID and T90QD showed significantly higher inhibition of platelet aggregation (P
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/de5c4dc4dc8c496383c79c8a75669210 Zobrazit plný text záznamu View record in DOAJ Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.